Rescheduling

Cannabis Rescheduling Support 'Spans Democrats, Republicans, Independents': Cresco Labs CEO

'It's The First Step, Not The Final Step': Cannabis Rescheduling Push Gains Broad Support

'No Turning Back Now': Cannabis Rescheduling Gains Momentum, Expert Offers Timeline

'It's The First Step, Not The Final Step': Cannabis Rescheduling Push Gains Broad Support

'No Turning Back Now': Cannabis Rescheduling Gains Momentum, Expert Offers Timeline

Federal Rescheduling: What It Could Mean For Cannabis Banking And Capital Markets

Cannabis Rescheduling Could Reverse 'Decades Of Misguided Drug Policy,' Says Key Industry Organization Following DEA Hearing Rescheduling (UPDATED)

Federal Rescheduling: What It Could Mean For Cannabis Banking And Capital Markets

Cannabis Rescheduling Could Reverse 'Decades Of Misguided Drug Policy,' Says Key Industry Organization Following DEA Hearing Rescheduling (UPDATED)

Cannabis Rescheduling: Will It Change The Industry Or Just Prolong The Wait?

Harris-Walz Could Spark 'Single Largest Catalyst' In Cannabis Industry, Says Expert

Rescheduling Recent News

Investor Confidence In Cannabis Is 'Amped Up' As VCs And Private Equity Firms Shift Perception, Expert Says

Investor confidence in cannabis industry rising due to regulatory changes, with growing interest from venture capital and private equity firms. Kevin Hart highlights progress and challenges at Benzinga Cannabis Capital Conference.

As Federal Rescheduling Gains Traction, This Cannabis Entrepreneur Wonders How Banking Factors In

Will Bowden, founder and CEO of Grasshopper Farms, who will speak at the upcoming Benzinga Cannabis Capital Conference in Chicago this October.

Will Federal Policy Changes Finally Free Cannabis Businesses From Tax Burdens?

Beau Whitney, founder and chief economist at Whitney Economics, shares his insights on potential financial benefits and global implications of rescheduling cannabis and enhanced access to banking services, ahead of the Benzinga Cannabis Capital Conference this October.

Federal Cannabis Shift: 'The Industry Is Projected To Surpass $100 Billion By 2030,' Says Expert

Justice Department proposes reclassifying marijuana from Schedule I to III, acknowledging its medical benefits but not legalizing recreational use. Federal involvement may increase regulatory complexity for financial institutions.

EXCLUSIVE: DOJ's Marijuana Rescheduling 'A Game-Changer For Profit Margins And Cash Flow'

The recent reclassification of marijuana by the Justice Department is expected to have a significant impact on the cannabis industry, particularly in New Jersey.

Anti-Cannabis Group Raises Money To Scuttle DEA Rescheduling Effort

Almost immediately following the DEA's announcement, "Smart Approaches to Marijuana" (SAM) began soliciting donations to oppose this change.

US Cannabis Council Calls DEA Historic Decision To Reclassify Cannabis 'A Tectonic Shift'

Conklin emphasized the importance of this decision, stating, "The US Cannabis Council strongly supports the move by the DEA"

DEA's Resistance To Cannabis Rescheduling Ignites Policy Clash

Growing discord between White House and DEA over rescheduling of marijuana. DEA cites unproven medical benefits and potential for abuse, in contrast to HHS findings.

EXCLUSIVE: 'Undo The Harms Of The War On Drugs,' Says Glass House CEO

Kyle Kazan, CEO of Glass House Brands, shares his thoughts on the cannabis industry, Greenhouse 5's impact, DEA rescheduling, and the importance of social justice.

Seattle Physician Launches Push To Reschedule Psilocybin For Medical Use

The DEA recently increased its quota for psilocybin for 2022, as well as for the legal production of psychedelic drugs such as MDMA and DMT, in response to heightened demand and